Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase.
In previous studies, we have shown that administration of monoclonal antibody (MoAb) C6B7 against human factor XII to baboons challenged with a lethal dose of Escherichia coli abrogates activation of the contact system and modulates secondary hypotension. To evaluate the contribution of activated contact proteases to the appearance of other inflammatory mediators in this experimental model of sepsis, we studied the effect of administration of MoAb C6B7 on activation of complement and fibrinolytic cascades, stimulation of neutrophil degranulation, and release of the proinflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). Activation of the complement system, as reflected by circulating C3b/c and C4b/c levels, was significantly reduced in five animals that had received MoAb C6B7 before a lethal dose of E coli as compared with five control animals that had been given a lethal challenge only. Inhibition of contact activation also modulated the fibrinolytic response, since the release of tissue-type plasminogen activator (t-PA) and the appearance of plasmin-alpha2-antiplasmin (PAP) complexes into the circulation was significantly attenuated upon pretreatment with anti-factor XII MoAb. In contrast, plasma levels of plasminogen activator inhibitor (PAI) were modestly enhanced in the treatment group. Degranulation of neutrophils, as assessed by circulating elastase-alpha1-protease inhibitor complexes, and release of IL-6 but not of TNF-alpha was decreased in anti-factor XII-treated animals. Observed differences in the inflammatory response between treatment and control groups were not likely due to different challenges, since the number of E coli that had been infused, as well as circulating levels of endotoxin after the challenge, were similar for both groups. These data suggest that activation of the contact system modulates directly or indirectly various mediator systems involved in the inflammatory response during severe sepsis in nonhuman primates.
Jansen
P M
PM
Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amersterdam, The Netherlands.
Pixley
R A
RA
Brouwer
M
M
de Jong
I W
IW
Chang
A C
AC
Hack
C E
CE
Taylor
F B
FB
Colman
R W
RW
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D016470:Bacteremia / Q000097:blood* / Q000628:therapy; D003167:Complement Activation / Q000187:drug effects*; D016207:Cytokines / Q000378:metabolism; D004927:Escherichia coli Infections / Q000097:blood* / Q000628:therapy; D005174:Factor XII / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects*; D007116:Immunization, Passive; D015850:Interleukin-6 / Q000378:metabolism*; D019272:Leukocyte Elastase; D051379:Mice; D009504:Neutrophils / Q000201:enzymology / Q000378:metabolism; D010196:Pancreatic Elastase / Q000378:metabolism*; D010215:Papio; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D012772:Shock, Septic / Q000097:blood* / Q000628:therapy; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D000979:alpha-2-Antiplasmin / Q000032:analysis
D000911:Antibodies, Monoclonal; D016207:Cytokines; D015850:Interleukin-6; D017395:Plasminogen Activator Inhibitor 1; D000979:alpha-2-Antiplasmin; D005174:Factor XII; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin